Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News GlaxoSmithKline to fast-track human trials of new Ebola vaccine

GlaxoSmithKline to fast-track human trials of new Ebola vaccine

29th August 2014

GlaxoSmithKline is on the verge of beginning human trials of a new Ebola vaccine following a fast-tracked development process made possible by an international collaboration.

The candidate vaccine, co-developed by the US National Institutes of Health and GlaxoSmithKline, could be given to healthy volunteers in the UK, Gambia and Mali as early as September as part of a phase I trial.

A 2.8 million pound grant from the Wellcome Trust, the Medical Research Council and the UK Department for International Development has made it possible for a University of Oxford team to carry out safety tests of the vaccine, with concurrent studies taking place in the US.

Funding support from the international consortium will also enable the company to begin manufacturing up to 10,000 additional doses of the vaccine at the same time as the initial clinical trials, meaning they can be made available immediately if the studies are successful.

Dr Moncef Slaoui, chairman of global research and development and vaccines at GlaxoSmithKline, said: "Today's announcement shows how private and public partners can pull together to respond to this critical public health emergency."

The current Ebola outbreak in west Africa has killed more than 1,400 people, making it one of the most widespread outbreaks of the disease ever recorded. The World Health Organization recently declared it a public health emergency of international concern.ADNFCR-8000103-ID-801745368-ADNFCR

We currently have 10 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.